

Pathophysiology of the respiratory system III – **Pulmonary blood flow**

Pulmonary circulation

Pulmonary hypertension definition & classification

– role of hypoxic pulmonary vasoconstriction and vascular remodelling


Pulmonary embolism

Pulmonary oedema


ARDS




Pulmonary vs. systemic circulation



- Lungs are the only organ through which **entire blood** passes!!!
 - the volume equals to the cardiac output (CO)
- The pressure is generated by the right ventricle (RV)
 - increased CO (e.g. physical activity) must be adopted by pulmonary circulation without a significant increase of the work of RV
 - see recruitment and distension of pulmonary vessels (capillaries)
 - therefore, given the differences in pressure and volume parameters in pulmonary bed, the **morphology of pulmonary vessels is different**
 - smaller amount of smooth muscle, larger distensibility by pressure and increased flow
 - however, smooth muscle of pulmonary arteries is very important – see hypoxic pulmonary vasoconstriction
- Pulmonary vascular resistance (PVR) varies between inspiration and expiration, i.e. with changing lung volume (see further)
- Lungs have a **dual blood supply**
 - deoxygenated blood from RV via pulmonary artery (PA)
 - systemic (nutritional) supply of conductive zone airways via bronchial circulation
 - branching from descending aorta
 - bronchial veins drain in small extent post capillary to pulmonary veins and are responsible for a physiological R-L shunt
- 4 main pulmonary veins drain into LA




The pulmonary capillary network




- The PA splits into left and right branches, further to smaller arteries and arterioles and finally to capillary network
 - this is a low-pressure system that **can expand two to three times the normal size before a significant increase in pulmonary capillary pressures is detectable**
 - normal PAP in a healthy adult ~22-25/8-10 mmHg (mPAP ~15 mmHg)
 - normal SAP in a healthy adult ~ 120/80 mmHg (mSAP ~96 mmHg)
 - under normal resting conditions, some pulmonary capillaries are closed and not perfused
- The pulmonary circulation has two mechanisms for lowering PVR when vascular pressures are increased because of increased blood flow
 - (1) recruitment = opening of previously closed capillary vessels
 - (2) distention = widening of capillary vessels


Recruitment and distension of pulmonary capillaries



Pulmonary vs. systemic circulation





- Pulmonary circulation
 - $\downarrow P$ / \downarrow resistance / \uparrow compliance
 - lower pressure gradient is sufficient to cover the distance between RV and LA
 - paradoxical response to $\downarrow P_{A\text{O}_2}$ (i.e. alveolar hypoxia) – vasoconstriction
 - with the aim to optimise V_A/\dot{Q} mismatch by redistribution of blood to well ventilated parts of the lungs
- Systemic circulation
 - $\uparrow P$ / \uparrow resistance / \downarrow compliance
 - massive pressure gradient necessary to cover large distance between LV and RA
 - typical response to $\downarrow P_{a\text{O}_2}$ (i.e. hypoxemia) – vasodilation
 - with the aim to increase perfusion and oxygen delivery




Pulmonary alveolar and extra-alveolar vessels


- **alveolar vessels**
 - capillaries of alveolar septa exposed to alveolar pressure (changing during inspiration and expiration)
 - they become compressed by inspiring
- **extra-alveolar vessels**
 - arteries and veins in interstitium paralleling branching of airways
 - together they create a „**broncho-vascular bundle**“
 - they are distended by radial traction of elastic elements of interstitium
 - therefore they become opened by inspiring
 - this is a compartment initially collecting fluid in lung oedema




Pulmonary vascular resistance - minimal at FRC




B DEPENDENCE OF VASCULAR RESISTANCE ON LUNG VOLUME




Relation between lung volume and PVR



- PVR is the main determinant of RV afterload and can increase significantly at both extremes of lung inflation
 - as lung volume increases from residual volume (RV) to total lung capacity (TLC), the “alveolar” vessels (red) become increasingly compressed by the distending lung units, and so their resistance increases
 - whereas the resistance of the “extra-alveolar” vessels (blue) falls as they become less tortuous and dilate with lung inflation
- During healthy conditions, these opposing effects of inflation normally optimize at functional residual capacity (FRC), assuming patency of all lung units



Pulmonary vascular resistance



Pulmonary vascular resistance

$$PVR = \frac{P_{\text{pulm artery}} - P_{L \text{ atrium}}}{\text{cardiac output}}$$

Remember: $\Delta P = Q \times R$, so $R = \Delta P / Q$

$$R = 8\eta l / \pi r^4$$

R = resistance

$P_{\text{pulm artery}}$ = pressure in pulmonary artery

$P_{L \text{ atrium}} \approx$ pulmonary capillary wedge pressure

η = viscosity of blood; l = vessel length;

r = vessel radius

$$SVR = \frac{\text{mean arterial pressure} - \text{mean right atrial pressure}}{Q_s \text{ (systemic blood flow)}}$$


$$PVR = \frac{\text{mean pulmonary artery pressure} - \text{mean left atrial pressure}}{Q_p \text{ (pulmonary blood flow)}}$$

Pulmonary hypertension (mPAP >25 mmHg) – diagnosis

- PH consists of a group of diseases with a resting mPAP ≥ 25 mmHg (≥ 25 mmHg during exercise)
 - initial diagnosis (or screening) by echocardiogram, however, Doppler estimates of PAP are inaccurate in many patients, and cannot be used to quantify RA, pulmonary venous, LA or LV pressures reliably
- PAP measured with right heart catheterization
- other parameters are necessary to classify and prognosticate patients appropriately
 - right ventricular end-diastolic pressure (RVEDP)
 - left ventricular end-diastolic pressure (LVEDP)
 - left heart catheterisation only in some patients (measurements of PV and LA pressure)
 - congenital heart defects or structural heart diseases
 - typically pulmonary blood flow and end-expiratory pulmonary artery wedge pressure (PAWP) commonly used as a surrogate of LVEDP



Table 1: Classification Pulmonary Hypertension

Group 1	Pulmonary Arterial Hypertension
Group 2	PH from left-sided heart disease
Group 3	PH from chronic hypoxic lung disease
Group 4	PH from chronic blood clots
Group 5	Unclear multifactorial mechanisms (sarcoidosis, hematological disorders, etc)





Right heart (PA) catheterization

- precise assessment of pressure waves generated by the different cardiac chambers
- performed by pulmonary artery catheter (frequently referred to as a Swan-Ganz catheter) following local anaesthesia via the femoral, jugular, brachial or subclavian vein access



Pulmonary hypertension (mPAP >25 mmHg) – pathogenesis

- pathogenesis is driven by **the triad of vasoconstriction, microthrombosis and remodelling of small pulmonary arteries**
- gfgf



Pulmonary hypertension (MPAP >25 mmHg) – classification


Table 1. Clinical Classification of Pulmonary Hypertension

Classification	Targeted treatment available?
Group 1*: Pulmonary arterial hypertension Including idiopathic, heritable, and HIV-associated; systemic sclerosis and other connective tissue disease; congenital heart disease; schistosomiasis; drug- and toxin-induced	Yes
Group 2: Pulmonary hypertension due to left heart disease Including systolic and diastolic dysfunction and valvular heart disease	No
Group 3: Pulmonary hypertension due to lung diseases and/or hypoxia Including chronic obstructive pulmonary disease, sleep-disordered breathing, and interstitial lung disease	No
Group 4: Chronic thromboembolic pulmonary hypertension	Yes
Group 5: Multifactorial pulmonary hypertension Including metabolic, systemic, and hematologic disorders (sickle cell disease), and others	No

HIV = human immunodeficiency virus.

*—Also includes 1' (pulmonary venoocclusive disease and/or pulmonary capillary hemangiomatosis) and 1" (persistent pulmonary hypertension of the newborn).


Information from references 3, 4, and 6.



- A–G level of the haemodynamic obstruction/problem:
 - A pulmonary arteries and arterioles
 - pulmonary arterial hypertension (group I)
 - pulmonary hypertension associated with lung diseases (group III)
 - B pulmonary venules: pulmonary veno-occlusive disease
 - C pulmonary veins: PV stenosis
 - D left atrium: stiff LA
 - E mitral valve: mitral stenosis, mitral regurgitation
 - F left ventricle: heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
 - G left ventricular outflow tract: aortic stenosis


Group 1: Pulmonary arterial hypertension (PAH)

- mPAP \geq 25 mmHg, PAWP \leq 15 mmHg (i.e. pre-capillary) and PVR $>$ 3 Wood Units
- types of PAH
 - idiopathic (iPAH) comprising the majority of cases
 - iPAH has been found to be strongly associated with female gender, family history and genetic variants, especially bone morphogenetic protein receptor type 2 (*BMPRII*) mutations
 - secondary to
 - connective tissue diseases (CTD)
 - congenital heart disease - hyperkinetic
 - at the end might lead to Eisenmenger's syndrome
 - drugs, toxins, HIV, schistosomiasis, portal hypertension, ...
- pre-capillary arterioles are affected by an angioproliferative vasculopathy that increases the PVR, thereby increasing the RV afterload with the resulting right heart failure being the ultimate cause of mortality
- management of PAH has advanced rapidly in recent years due to improved understanding of the pathophysiology revealing a disruption of three key signalling pathways
 - nitric oxide (NO)
 - phosphodiesterase 5 inhibitors (PDE-5i)
 - guanylate cyclase (GC) stimulators
 - prostacyclin (PGI₂) - thromboxane A₂ (TXA₂)
 - prostacyclin analogues and receptor agonists
 - endothelin-1 (ET-1)
 - endothelin receptor antagonists (ERAs) available as ET_A selective or dual-action on ET_A and ET_B receptors



PAH due to CHD – Eisenmenger's syndrome

- PAH develops in CHD patients as a result of increased pulmonary blood flow due to the presence of a left-to-right shunts
 - simple
 - atrial septal defect (ASD)
 - ventricular septal defects (VSD)
 - patent ductus arteriosus
 - complex
 - complete atrioventricular septal defect (AVSD)
 - truncus arteriosus
 - single ventricle
 - transposition of the great arteries with
- Eisenmenger's syndrome = reversal of the initial L-R shunt to the right-to-left (pulmonary-to-systemic) shunt due to remodelling of pulmonary vasculature




Group 2: PH due to left heart disease (PH-LHD)

Symptoms and Clinical presentations

- Exertional dysnoea and exercise intolerance
- Elderly female (>60 years)
- Present with multiple comorbidities (eg. obesity, diabetes mellitus, hypertension, renal dysfunction, coronary artery disease, and atrial fibrillation)

Chest X-ray

- Pleural effusions
- Pulmonary oedema
- Pulmonary congestion




Blood test

- BMP $\geq 35\text{pg/ml}$ and/or
- NT-proBNP $\geq 125\text{pg/ml}$

Echocardiography

- LA/RA enlargement
- LV/RV hypertrophy
- LV diastolic dysfunction
- Preserved LV systolic function (eg. LVEF $\geq 50\%$, LVEDV $< 97\text{ml/m}^2$)

Right heart catheterization



mPAP

At rest $\geq 25\text{mmHg}$
During exercise* $> 30\text{mmHg}$




PAWP

$> 15\text{mmHg}$
 $\geq 25\text{mmHg}$

Pre-capillary component


Absence



lcPH

DPG $< 7\text{mmHg}$
PVR ≤ 3 Wood units

Presence




CpcPH

$\geq 7\text{mmHg}$
 > 3 Wood units



The Journal of
Physiology

- mPAP ≥ 25 mmHg, PAWP > 15 mmHg (i.e. post-capillary) and PVR normal (< 3 Wood Units)
- causes
 - adult population
 - systolic or diastolic heart failure (HFpEF or HFrEF)
 - pulmonary vascular complications of heart failure with preserved ejection fraction
 - valvular disease
 - paediatric population
 - anatomical left-sided obstruction (e.g., valvar aortic stenosis, coarctation of the aorta, obstructive hypertrophic cardiomyopathy and others)

Progression left heart disease to congestive heart failure




Lung congestion can lead to oedema in LHD




Fluid balance in the lungs


- determined by
 - capillary hydrostatic pressure
 - low but still higher than pressure in the interstitium
 - colloid osmotic pressure
 - higher in capillaries than in interstitium, therefore opposes the hydrostatic pressure
 - capillary permeability (leakiness)
- in total, very small amount of fluid leaks into interstitial space and this amount is drained by lymphatics





PULMONARY CAPILLARY FLUID BALANCE



Koeppen & Stanton: Berne and Levy Physiology, 6th Edition.
Copyright © 2008 by Mosby, an imprint of Elsevier, Inc. All rights reserved




Pulmonary lymphatics



- lymphatics start in the interstitial space between the alveolar cells and the capillary endothelium of the pulmonary arterioles
 - the tracheobronchial lymph nodes are arranged in five main groups:
 - paratracheal, superior tracheobronchial, subcarinal, bronchopulmonary and pulmonary


Alveolar fluid clearance



- The alveolar epithelium is composed of squamous Alveolar Type I (AT I) and cuboidal Alveolar Type II (AT II) cells
- Both AT I and AT II cells contain amiloride-sensitive epithelial Na channels as well as Na⁺/K⁺-ATPase which are involved in alveolar transepithelial sodium transport
- In addition, AT I cells have aquaporin 5, which contributes to either water or gas exchange
- AT II cells have the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) and Chlorine (Cl⁻) channels, which mediate apical Cl⁻ transport
- The tight junctions (a chain in grey between Alveolar Epithelial Cells (AECs)) and adherens junctions (in red between AECs) between adjacent alveolar epithelial cells provide a physical barrier from paracellular solute transport



Lung oedema

- interstitial or alveolar oedema
- cardiogenic
 - result of acute decompensation of left sided heart failure
 - commonly precipitated by fluid overload, rise in BP (hypertensive emergency), myocardial infarction, acute valvular disease, tachyarrhythmia, acute renal injury
- non-cardiogenic = direct injury to alveoli (inflammation) increasing capillary permeability
 - serious clinical form is denoted as acute respiratory distress syndrome (ARDS)
 - causes
 - external
 - pulmonary infection
 - inhalation of toxic substances or aspiration
 - chest trauma
 - internal
 - sepsis
 - low oncotic pressure
- consequences – an impaired gas exchange
 - diffusion impairment
 - change of lung compliance – intrinsic restrictive ventilation disease





Group 3: PH due to lung disease and/or chronic hypoxia

- causes - chronic
 - COPD
 - interstitial lung disease
 - scarring and inflammation in the lungs
 - overlap syndromes
 - conditions that cause hypoxemia
 - obstructive sleep apnea
 - alveolar hypoventilation disorders
 - chronic exposure to hypoxia – high altitude
- mechanisms (thin air = thick vessels)
 - acute hypoxia leads to vasoconstriction occurring due to alterations in redox and NO signaling and release of vasoactive mediators
 - vessel remodeling in the context of sustained hypoxic exposure due to HIF-dependent processes




Hypoxic pulmonary vasoconstriction (HPV)

- a physiological phenomenon in which small pulmonary arteries constrict in the presence of **alveolar hypoxia** (low oxygen levels)
 - as in **hypoventilation** and **low V_A/Q ratio**
 - typically in obstructive diseases (since these are chronic) resistant to compensatory hyperventilation such as chronic bronchitis
- a homeostatic mechanism that is intrinsic to the pulmonary vasculature
 - intrapulmonary arteries constrict in response to alveolar hypoxia, diverting blood to better-oxygenated lung segments, thereby **optimizing ventilation/perfusion matching and systemic oxygen delivery**
 - chronically happens with low V/Q ratio (and event. in long-lasting hypoventilation)
- mechanisms involve (in brief)
 - in response to alveolar hypoxia, a mitochondrial sensor dynamically changes reactive oxygen species and redox couples in pulmonary artery smooth muscle cells (PASMC)
 - this inhibits potassium channels, depolarizes PASMC, activates voltage-gated calcium channels, and increases cytosolic calcium, causing vasoconstriction
 - sustained hypoxia activates rho kinase, reinforcing vasoconstriction, and hypoxia-inducible factor (HIF)-1 α , leading to adverse pulmonary vascular remodelling and **pulmonary hypertension** (PH)
 - this pre-capillary PH leads to right heart remodelling – **cor pulmonale**




Mechanism of HPV

The current model of the cellular mechanism of hypoxic pulmonary vasoconstriction in a rat pulmonary artery (PA). Relevant ion channels are displayed. Under normoxia, the membrane potential of the smooth muscle of the PA is held at approximately -50 mV because of the TASK-like background current of a K^+ channel. Hypoxic conditions initially decrease TASK activity. When combined with TXA_2 , activation of NSC induces membrane depolarization up to the threshold voltage for activation of K_v channels (Step 1). In addition to the NSC activation, hypoxic inhibition of the K_v current further depolarizes the membrane potential (Step 2). As the membrane potential depolarizes above -40 mV, the activation of $VOCC_L$ eventually allows for Ca^{2+} influx for contraction of smooth muscles. K_v , voltage-gated K^+ channel; NSC, nonselective cation channel; TASK-1, background-type K^+ channel with a two-pore domain (K2P); TXA_2 , thromboxane A₂; $VOCC_L$, voltage-gated L-type Ca^{2+} channels.



Primary role in non-ventilated foetal lung where HPV diverts blood to the systemic vasculature






Koeppen & Stanton: Berne and Levy Physiology, 6th Edition.
Copyright © 2008 by Mosby, an imprint of Elsevier, Inc. All rights reserved


- at birth
 - lung inflation and reaching stable volumes
 - surfactant
 - pulmonary blood flow
 - increase of alveolar P_AO_2 relieves HPV and leads to vasodilation
 - subsequent circulatory changes (closure of foetal shunts)
 - resorption of fluid from alveoli
 - role of pneumocytes

Group 4: Chronic thromboembolic PH (CTEPH)

- ~50% of CTEPH patients never have had a specific episode of thrombosis that they recall
 - meaning typically deep vein thrombosis (DVT) event. followed by pulmonary embolism
 - DVT frequency: calf, popliteal, femoral, pelvic, portal, hepatic (Budd-Chiari sy), renal vein in nephrotic sy
 - PE frequency: femoral (and other above knee)
 - dg. venous duplex US + d-dimers (active fibrinolysis)
 - superficial thrombophlebitis might co-exist with DVT!
 - PE severity
 - acute – small, sub-massive and massive (haemodynamic instability)
 - saddle PE
 - chronic
- it is therefore important to rule out CTEPH on every PH patient as it is a potentially curable disease
 - pulmonary angiogram
 - perfusion (V/Q) scan



CETPH



- 3%-5% of all PE cases due to organised blood clot following
 - acute PE
 - recurrent PE (successive)
- treated invasively by
 - pulmonary thromboendarterectomy (PTE)
 - percutaneous balloon angioplasty
 - lifelong anticoagulation

